Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER ^þ /HER2 ^þ breast cancers: Implications to the EXTENET trial

Medicine & Life Sciences

• N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 100%
• Fulvestrant 76%
• Breast Neoplasms 36%
• Trastuzumab 15%
• Cyclin D1 13%
• pertuzumab 9%
• Therapeutics 9%
• Gene Expression 7%
• MCF-7 Cells 6%
• Paclitaxel 6%
• Reporter Genes 6%
• Disease-Free Survival 5%
• Research Design 5%
• Cell Cycle 5%
• Down-Regulation 4%
• Phosphorylation 4%
• Placebos 4%
• Neoplasms 4%
• Cell Line 3%
• Growth 3%